Arthelio®
An innovative postbiotic for people with osteoarthritis and joint and mobility disorders.
Arthelio® is an innovative postbiotic for people with osteoarthritis and joint and mobility disorders.
Did you know that a leaky gut can play a role in the inflammation and even degradation of cartilage?
Supported by 30 years of academic research and 5 years of product development, Arthelio® is the first microbiotic innovation for people with osteoarthritis and joint/mobility disorders.
Why choose Arthelio®?
Arthelio® is the first microbiotic innovation in joint health, and is backed by decades of research.
- Supported by 30 years of academic research
- 5 years of product development
- Unique and patented innovation for people with osteoarthritis and joint/mobility disorders
Innovation backed by 30 years of scientific research
If there is an imbalance in the gut, then more bacteria may penetrate the intestinal wall. This results in more pro-inflammatory molecules in the blood, which trigger the immune system and consequently cause inflammation in the joints. This is known as the gut-joint axis. It is this inflammation which leads to the cartilage degradation that affects people with osteoarthritis.
Our recent white paper examines the causes, symptoms and impact of osteoarthritis, along with existing treatments. It goes on to show how Arthelio® can transform osteoarthritis management.
How does Arthelio® help?
- Harnesses the power of B. longum lysate (CBi0703®) and vitamin C in synergy to help improve mobility, comfort and quality of life.
- Vitamin C contributes to collagen formation, healthy cartilage and normal joint functionality.
- Lysate of B. longum CBi0703® helps prevent bacteria from going through the intestinal wall and consequently reduces inflammation in the joints.
Regulatory and certifications
This solution is unique and patented.
- Ingredient manufactured under GMP Pharma rules.
- The product Arthelio® complies with the CE regulation 1169/2011
- Non-GMO, gluten-free
Why choose ABbiotek Health?
- We provide tailored microbiome solutions to address specific health challenges including Digestive, Immunity and Mobility disorders.
- We’re dedicated to providing a natural-first option to complement conventional drugs.
- Our teams of experts use proven fermentation technology to get bacteria, yeasts, and enzymes (BYE) working in synergy to produce innovative ingredients for the pharma, medical nutrition, food, nutraceutical and pet care industries.
- We have an advanced supply chain infrastructure which gives us the ability to service customers across the globe
References
1. Huang ZY, Stabler T, Pei FX, Kraus VB. Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation. Osteoarthritis Cartilage. 2016 Oct;24(10):1769-1775. doi: 10.1016/j.joca.2016.05.008. Epub 2016 May 20. PMID: 27216281; PMCID: PMC5026878.
2. Henrotin Y, Patrier S, Pralus A et al. Protective Actions of Oral Administration of Bifidobacterium longum CBi0703 in Spontaneous Osteoarthritis in Dunkin Hartley Guinea Pig Model. Cartilage 2019: 1947603519841674. doi: 10.1177/1947603519841674.
3. Adami G. Bifidobacterium longum CBi0703® e vitamina C in pazienti con gonartrosi e coxartrosi. Giornale Italiano di Ortopedia e Traumatologia 2023;49:195-202; https://doi.org/10.32050/0390-0134-N414
4. Breban M and Henrotin Y. L’arthrose: La piste du microbiote vers un nouveau paradigme? Rhumatos 2020, 17(157) :2
This website is intended to provide information about ABbiotek Health’s ingredients, used in various food/dietary supplement products around the world. It is only intended for business to business and to provide information to food/dietary supplement professionals and is not designed for the general public. Statements used on this website have not been evaluated by the Food and Drug Administration or any other competent authority. Products are not intended to diagnose, treat, cure or prevent any disease.